Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
A1: AMG 386/kg+ Liposomal doxorubicin · 1 trial · 9 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy \[(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)\]. |
| Part 2 | EXPERIMENTAL | The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1 |
| Name | Type | Description |
|---|---|---|
| A1: AMG 386 10 mg/kg + Liposomal doxorubicin | DRUG | Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW |
| A3: AMG 386 15mg/kg + Liposomal doxorubicin | DRUG | A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W |
| B1: AMG 386 10 mg/kg + Topotecan | DRUG | B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule |
| B3: AMG 386 15mg/kg + Topotecan | DRUG | AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule |
Inclusion Criteria: * Histologically or cytologically documented recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer * Subjects must have received at least one platinum containing regimen * Radiographically documented progression per RECIST criteria with modification...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AMG 386 is an investigational small molecule being studied for the treatment of cancer, specifically in combination with pegylated liposomal doxorubicin or topotecan in patients with advanced recurrent epithelial ovarian cancer, as well as other solid tumors and gynecological malignancies. It is being developed by Amgen Inc. and is currently in Phase 1 clinical development.
AMG 386 is an investigational small molecule that targets the angiopoietin pathway. It is being studied in combination with either pegylated liposomal doxorubicin or topotecan for the treatment of advanced recurrent epithelial ovarian cancer and other solid tumors. The drug is in Phase 1 clinical development by Amgen Inc.
AMG 386 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is currently in Phase 1 clinical development for the treatment of cancer, including advanced recurrent epithelial ovarian cancer and other solid tumors.
AMG 386 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of cancer, including advanced recurrent epithelial ovarian cancer and other solid tumors. The drug has completed one Phase 1 trial and is not yet approved by regulatory authorities.
AMG 386 has been studied in one completed Phase 1 clinical trial with the identifier NCT00770536. This trial evaluated AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in female patients with advanced recurrent epithelial ovarian cancer, as well as other solid tumors and gynecological malignancies.
AMG 386 is also known as trebananib. It is an investigational small molecule being developed by Amgen Inc. for the treatment of cancer, including advanced recurrent epithelial ovarian cancer and other solid tumors. The drug is currently in Phase 1 clinical development.